Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis.
Τίτλος | Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. |
Publication Type | Journal Article |
Year of Publication | 2010 |
Authors | Kirmizis, D., Papagianni A., Dogrammatzi F., Skoura L., Belechri A-M., Alexopoulos E., Efstratiadis G., & Memmos D. |
Journal | J Atheroscler Thromb |
Volume | 17 |
Issue | 12 |
Pagination | 1256-65 |
Date Published | 2010 Dec 26 |
ISSN | 1880-3873 |
Λέξεις κλειδιά | Apoptosis, Biological Markers, C-Reactive Protein, Case-Control Studies, Endothelial Cells, Humans, Hypolipidemic Agents, Inflammation, Kidney Failure, Chronic, Lipids, Monocytes, Oxidative Stress, Renal Dialysis, Simvastatin |
Abstract | AIM: We investigated the effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in hyperlipidemic endstage renal disease patients on chronic hemodialysis (HD).METHODS: In 25 hyperlipidemic HD patients who received 10 mg of simvastatin for 6 months and another 25 controls, the extended lipid profile and serum hsIL-6, MCP-1, sICAM-1, sVCAM-1, and sE-selectin, plasma oxLDL, and serum sFas and sFasL levels were determined at baseline, 3 months and 6 months. In 18 patients of the simvastatin group, the expression of CD14, CD16, CD62L and CD64 on monocyfes was determined with flow cytometry.RESULT: Simvastatin treatment resulted in significant reductions in serum lipid levels at 3 months and beyond, compared to at baseline. Moreover, at 6 months, simvastatin caused a significant reduction in CRP (p < 0.001), which correlated to the decrease in total and LDL cholesterol levels, as well as a significant reduction in IL-6 (p=0.001), sICAM-1 (p < 0.001), sVCAM-1 (p < 0.001), oxLDL (p=0.001), sFas (p=0.02) and CD14 expression (p < 0.001), compared to baseline values. No significant changes in the controls were noticed during the study.CONCLUSION: In conclusion, in hyperlipidemic HD patients, simvastatin treatment resulted in a significant reduction in markers of endothelial dysfunction, inflammation, oxidative stress, endothelial cell apoptosis and peripheral blood monocyte stimulation. The reduction in CRP appears to be related to the lipid-lowering effects of simvastatin. |
Alternate Journal | J. Atheroscler. Thromb. |
PubMed ID | 20885069 |